WO2020072519A1 - Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy - Google Patents
Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapyInfo
- Publication number
- WO2020072519A1 WO2020072519A1 PCT/US2019/054107 US2019054107W WO2020072519A1 WO 2020072519 A1 WO2020072519 A1 WO 2020072519A1 US 2019054107 W US2019054107 W US 2019054107W WO 2020072519 A1 WO2020072519 A1 WO 2020072519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- ptcl
- cell lymphoma
- drug conjugate
- administered
- Prior art date
Links
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 title claims abstract description 76
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 title claims abstract description 75
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 title claims abstract description 75
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 70
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 66
- 238000002560 therapeutic procedure Methods 0.000 title description 27
- 238000002512 chemotherapy Methods 0.000 claims abstract description 17
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 48
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 44
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 35
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 34
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 22
- 229960004397 cyclophosphamide Drugs 0.000 claims description 22
- 229960004679 doxorubicin Drugs 0.000 claims description 22
- 229960004618 prednisone Drugs 0.000 claims description 22
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 22
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 19
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims description 19
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 19
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 18
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000002648 combination therapy Methods 0.000 claims description 15
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 13
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 claims description 10
- 108010016626 Dipeptides Proteins 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 229960002173 citrulline Drugs 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 3
- 235000013477 citrulline Nutrition 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 47
- 230000004083 survival effect Effects 0.000 description 25
- 206010025323 Lymphomas Diseases 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 238000012552 review Methods 0.000 description 11
- 208000017604 Hodgkin disease Diseases 0.000 description 10
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 10
- 229960004528 vincristine Drugs 0.000 description 10
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 208000037821 progressive disease Diseases 0.000 description 9
- 238000009093 first-line therapy Methods 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 201000005962 mycosis fungoides Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 4
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 108010044023 Ki-1 Antigen Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068977 polysorbate 20 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 238000009104 chemotherapy regimen Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 2
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229920001184 polypeptide Chemical group 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000031134 Meningeal disease Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000011395 multi-agent chemotherapy Methods 0.000 description 1
- 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000013707 sensory perception of sound Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure relates, in general, to methods of treating a peripheral T cell lymphoma by administering an anti-CD30 antibody drug conjugate therapy, in combination with a chemotherapeutic regimen of cyclophosphamide, doxorubicin and prednisone.
- Peripheral T-cell lymphoma is a heterogeneous group of aggressive non- Hodgkin lymphoma (NHL).
- NHL non- Hodgkin lymphoma
- PTCL accounts for approximately 10% of all NHL cases in the US and Europe, and may be as high as 24% in Asia.
- the most common PTCL subtypes including PTCL-not otherwise specified (PTCL-NOS), Angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase (ALK)-positive/negative anaplastic large cell lymphoma (ALCL), represent more than half of the cases of PTCL and are treated similarly 1 .
- PTCL-NOS PTCL-not otherwise specified
- AITL Angioimmunoblastic T-cell lymphoma
- ALK anaplastic lymphoma kinase-positive/negative anaplastic large cell lymphoma
- CD30-positive peripheral T-cell lymphoma is an aggressive lymphoid neoplasm that often presents as advanced-stage, symptomatic disease. These types of lymphoma are difficult to treat and are often grouped together for enrollment in clinical trials based on their universally dismal outcomes.
- OS 5-year overall survival
- PTCL The most common frontline treatment of PTCL is anthracycline-based chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens which do not result in durable remissions for the majority of patients.
- anthracycline-containing regimens resulted in suboptimal overall response rates ranging from 39% to 84% with low numbers of complete remissions.
- the present disclosure provides methods for treating peripheral T cell lymphoma comprising administering an anti-CD30 antibody-drug conjugate administered in combination with a chemotherapy regimen.
- the therapeutic regimen may include chemotherapeutics known in the field of cancer treatment. Exemplary chemotherapeutics are disclosed in greater detail in the Detailed Description.
- the methods herein include treatment comprising a chemotherapy consisting essentially of
- cyclophosphamide doxorubicin and prednisone (CHP).
- the disclosure provides a method of administering an anti-CD30 drug conjugate, e.g., brentuximab vedotin, to a subject having a peripheral T cell lymphoma every three weeks.
- the peripheral T cell lymphoma may be more particularly diagnosed as, for example, systemic anaplastic large cell lymphoma (sALCL), angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), Adult T- Cell Leukemia/Lymphoma (ATLL), Enteropathy-associated T-cell lymphoma (EATL) and Hepatosplenic T-cell lymphoma.
- the anti-CD30 antibody drug conjugate is administered at a dose of 1.8 mg/kg.
- the PTCL is a sALCL.
- the sALCL is selected from the group consisting of anaplastic lymphoma kinase positive (ALK+) sALCL and anaplastic lymphoma kinase negative (ALK-) sALCL.
- the sALCL is an ALK+ sALCL.
- the sALCL is an ALK- sALCL.
- the PTCL is not a sALCL.
- the PTCL is selected from the group consisting of angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), Adult T-Cell
- ATLL Enteropathy-associated T-cell lymphoma
- TLL Enteropathy-associated T-cell lymphoma
- the PTCL is not an AITL.
- the PTCL is selected from the group consisting of systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), Adult T-Cell
- ATLL Enteropathy-associated T-cell lymphoma
- TLL Enteropathy-associated T-cell lymphoma
- the subject has an International Prognostic Index (IPI) score of 0 or 1. In various embodiments, the subject has an International Prognostic Index (IPI) score 3 2. In various embodiments, the subject has an International Prognostic Index (IPI) score of 2 or 3. In various embodiments, the subject has an International Prognostic Index (IPI) score 3 4. In various embodiments, the subject has an International Prognostic Index (IPI) score of 4 or 5.
- IPI International Prognostic Index
- the subject has a Baseline ECOG Status of 0 or 1 . In various embodiments, the subject has a Baseline ECOG Status of 2.
- the subject is newly disgnosed with PTCL and/or has not previously been treated for a hematologic cancer.
- the subject has previously been treated for a hematologic cancer.
- the cancer has relapsed or is refractory.
- the PTCL is a stage III or stage IV PTCL.
- the PTCL is a CD30-expressing PTCL tumor. In various embodiments, the PTCL is a CD30-expressing PTCL and the CD30 expression is 310% of lymphoma cells.
- the CD30 expression is measured by a FDA approved test.
- exemplary tests include local pathology assessment in a CD30-qualified laboratory; CD30 positivity confirmed in diagnostic biopsy using immunohistochemistry. The 3 following criteria were used to declare CD30 positivity:
- CD30 detected in 10% or greater of neoplastic cells in cases where enumeration of neoplastic cells was not possible, total lymphocytes may have been used).
- CD30 staining at any intensity above background in cases where enumeration of neoplastic cells was not possible, total lymphocytes may have been used.
- the combination therapy is administered every three weeks.
- the combination therapy is administered on day 1 of a 21 day cycle.
- the ADC + CHP combination therapy is administered for no more than eight cycles.
- the ADC +CHP combination therapy is administered for six to eight cycles.
- the A+CHP therapy is administered for 4, 5, 6, 7 or 8 cycles.
- the subject receives single-agent anti-CD30 antibody drug conjugate, e.g., brentuximab vedotin, for eight to 10 additional cycles for a total of 16 cycles.
- the anti-CD30 antibody drug conjugate is administered at 1.8 mg/kg with CHP combination therapy.
- the ADC or combination therapy is administered until a PET scan determines there is no tumor or progression of tumor.
- the anti-CD30 antibody of the anti-CD30 antibody drug conjugate comprises i) a heavy chain CDR1 set out in SEQ ID NO: 4, a heavy chain CDR2 set out in SEQ ID NO: 6, a heavy chain CDR3 set out in SEQ ID NO: 8; and ii) a light chain CDR1 set out in SEQ ID NO: 12, a light chain CDR2 set out in SEQ ID NO: 14, and a light chain CDR13 set out in SEQ ID NO: 16.
- the anti-CD30 antibody of the anti-CD30 antibody drug conjugate also comprises i) an amino acid sequence at least 85% identical to a heavy chain variable region set out in SEQ ID NO: 2 and ii) an amino acid sequence at least 85% identical to a light chain variable region set out in SEQ ID NO: 10. It is contemplated that the amino acid variable region sequence can be 90%, 95%, 96% 97%, 98% or 99% identical to either SEQ ID NO: 2 or SEQ ID NO: 10.
- the anti-CD30 antibody of the anti-CD30 antibody drug conjugate is a monoclonal anti-CD30 antibody. In various embodiments, the anti-CD30 antibody of the anti-CD30 antibody drug conjugate is a chimeric AC10 antibody.
- the antibody drug conjugate comprises monomethyl auristatin E and a protease-cleavable linker.
- the protease cleavable linker is comprises a thiolreactive spacer and a dipeptide.
- the protease cleavable linker consists of a thiolreactive maleimidocaproyl spacer, a valine— citrulline dipeptide, and a p-amino-benzyloxycarbonyl spacer.
- the antibody is an IgG antibody, preferably an lgG1 antibody.
- the anti-CD30 antibody drug conjugate is brentuximab vedotin.
- the subject is also receiving a chemotherapy consisting essentially of cyclophosphamide, doxorubicin and prednisone (CHP) as a combination therapy.
- a chemotherapy consisting essentially of cyclophosphamide, doxorubicin and prednisone (CHP) as a combination therapy.
- the cyclophosphamide is administered at 750 mg/m 2
- doxorubicin is administered at 50 mg/m 2
- prednisone is administered at 100 mg on days 1 to 5 of a 21 day cycle.
- the anti-CD30 antibody drug conjugate is brentuximab vedotin and is administered at 1 .8 mg/kg, cyclophosphamide is administered at 750 mg/m 2 , doxorubicin is administered at 50 mg/m 2 , and prednisone is administered at 100 mg on days 1 to 5 of a 21 day cycle.
- the disclosure provides a method of treating a subject having peripheral T cell lymphoma comprising administering as frontline treatment an effective amount of a composition comprising bretuximab vedotin (A) in combination with chemotherapy consisting of cyclophosphamide, doxorubicin and prednisone (CHP), wherein the brentuximab vedotin is administered at 1 .8 mg/kg every two weeks, cyclophosphamide is administered at 750 mg/m 2 on day 1 of a 21 day cycle, doxorubicin is administered at 50 mg/m 2 on day 1 of a 21 day cycle, and prednisone is administered at 100 mg on days 1 to 5 of a 21 day cycle, until a maximum of eight cycles, and wherein the brentuximab vedotin is administered within about 1 hour after administration of the CHP therapy; optionally the subject is characterized by one or more of the following: (1 ) ALK
- the methods herein further provide that progression free survival (PFS) of the subject after therapy is maintained for greater than 1 year. In various embodiments, the progression free survival (PFS) of the subject after therapy is maintained for approximately 2 years. In certain embodiments, after six to eight cycles of A+CHP therapy the subject has a Deauville score of 3 or less, or 2 or less. [0027] It is specifically provided herein that all aspects of the disclosure described above with the methods of treatment are applicable to the anti-CD30 antibody drug conjugate for use in any of the indications described above.
- the present disclosure provides methods for treating peripheral T cell lymphomas comprising administering an anti-CD30 antibody drug conjugate, optionally in combination with a chemotherapeutic regimen.
- “Therapeutically effective amount” as used herein refers to that amount of an agent effective to produce the intended beneficial effect on health.
- A“therapy” as used herein refers to either single agent therapy with anti-CD30 antibody drug conjugate or a combination therapy comprising anti-CD30 drug conjugate in combination with a chemotherapeutic regimen.
- a preferred embodiment includes combination therapy comprising administering an anti-CD30 antibody drug conjugate with a chemotherapy consisting essentially of cyclophosphamide, doxorubicin and prednisone (CHP therapy).
- Antibody +CHP therapy refers to treatment of a subject with an anti-CD30 antibody drug conjugate as described herein in combination with chemotherapy consisting essentially of cyclophosphamide, doxorubicin and prednisone therapy (CHP therapy).
- Lymphomas as used herein is hematological malignancy that usually develops from hyper-proliferating cells of lymphoid origin. Lymphomas are sometimes classified into two major types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Lymphomas may also be classified according to the normal cell type that most resemble the cancer cells in accordance with phenotypic, molecular or cytogenic markers. Lymphoma subtypes under that classification include without limitation mature B-cell neoplasms, mature T cell and natural killer (NK) cell neoplasms, Hodgkin lymphoma and immunodeficiency-associated lympho-proliferative disorders.
- HL Hodgkin lymphoma
- NHL non-Hodgkin lymphoma
- Lymphoma subtypes include precursor T-cell lymphoblastic lymphoma (sometimes referred to as a lymphoblastic leukemia since the T-cell lymphoblasts are produced in the bone marrow), follicular lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, B-cell chronic lymphocytic lymphoma (sometimes referred to as a leukemia due to peripheral blood involvement), MALT lymphoma, Burkitt's lymphoma, mycosis fungoides and its more aggressive variant Sezary's disease, peripheral T-cell lymphomas not otherwise specified, nodular sclerosis of Hodgkin lymphoma, and mixed-cellularity subtype of Hodgkin lymphoma.
- T-cell lymphoblastic lymphoma sometimes referred to as a lymphoblastic leukemia since the T-cell lymphoblasts are produced in the bone marrow
- follicular lymphoma diffuse large B cell lymphoma
- Peripheral T Cell lymphoma refers to a subset of heterogeneous, aggressive non- Hodgkin lymphoma (NHL). As used herein“peripheral” does not refer to the extremities, but identifies PTCL as a cancer that arises in the lymphoid tissues outside of the bone marrow, such as lymph nodes, spleen, gastrointestinal tract, and skin (e.g., cutaneous peripheral T cell lymphoma). (Lymphoma Research Foundation
- hltps://www.iymphoma.orq/aboutlymphoma / nh!/ptcl/ PTCL can include involvement of T cells and natural killer (NK) cells.
- PTCL are different than cutaneous T cell lymphoma (CTCL), which originate in the skin.
- Peripheral T cell lymphoma includes systemic anaplastic large cell lymphoma (sALCL), angioimmunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma- not otherwise specified (PTCL-NOS), Adult T-Cell Leukemia/Lymphoma (ATLL), Enteropathy- associated T-cell lymphoma (EATL) and Hepatosplenic T-cell lymphoma. See below
- Threshold 4 Threshold 4* Threshold 5
- Haematologica http://www.haematologica.Org/content/98/8/e81 : CD30 expression by subtype
- Leukemia as the term is used herein is a hematological malignancy that usually develops from hyper-proliferating cells of myeloid origin, and include without limitation, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML) and acute monocyctic leukemia (AMoL).
- ALL acute lymphoblastic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- AoL acute monocyctic leukemia
- Other leukemias include hairy cell leukemia (HCL), T-cell lymphatic leukemia (T-PLL), large granular lymphocytic leukemia and adult T-cell leukemia.
- pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
- pharmaceutically compatible ingredient refers to a pharmaceutically acceptable diluent, adjuvant, excipient, or vehicle with which an antibody-drug conjugate is administered.
- the term "monoclonal antibody” refers to an antibody that is derived from a single cell clone, including any eukaryotic or prokaryotic cell clone, or a phage clone, and not the method by which it is produced. Thus, the term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology.
- nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence. To determine the percent identity, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
- the molecules are identical at that position.
- substantially identical in the context of two nucleic acids or polypeptides, refers to two or more sequences or subsequences that have at least 70% or at least 75% identity; more typically at least 80% or at least 85% identity; and even more typically at least 90%, at least 95%, or at least 98% identity (for example, as determined using one of the methods set forth below).
- the determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
- a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877.
- Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al., 1990, J. Mol. Biol. 215:403-410.
- Gapped BLAST can be utilized as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402.
- PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Id.).
- MMAE monomethyl auristatin E
- PAB refers to the self-immolative spacer
- MC refers to the stretcher maleimidocaproyl:
- cAC10-MC-vc-PAB-MMAE refers to a chimeric AC10 antibody conjugated to the drug MMAE through a MC-vc-PAB linker.
- An anti-CD30 vc-PAB-MMAE antibody-drug conjugate refers to an anti-CD30 antibody conjugated to the drug MMAE via a linker comprising the dipeptide valine citrulline and the self-immolative spacer PAB as shown in Formula (I) of US Patent No. 9,21 1 ,319.
- Murine anti-CD30 mAbs known in the art have been generated by immunization of mice with Hodgkin’s disease (HD) cell lines or purified CD30 antigen.
- AC10 originally termed C10 (Bowen et al., 1993, J. Immunol. 151 :5896 5906), is distinct in that this anti-CD30 mAb that was prepared against a hum an NK-like cell line, YT (Bowen et al., 1993, J. Immunol. 151 :5896 5906).
- the signaling activity of this mAb was evidenced by the down regulation of the cell surface expression of CD28 and CD45 molecules, the up regulation of cell surface CD25 expression and the induction of homotypic adhesion following binding of C10 to YT cells.
- antibodies of the disclosure immunospecifically bind CD30 and exert cytostatic and cytotoxic effects on malignant cells in Hodgkin’s disease and mature T cell lymphoma.
- Antibodies of the disclosure are preferably monoclonal, and may be multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, and CD30 binding fragments of any of the above.
- the immunoglobulin molecules of the disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2) or subclass of immunoglobulin molecule.
- the antibodies are human antigen-binding antibody fragments of the present disclosure and include, but are not limited to, Fab, Fab' and F(ab') 2 , Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V L or V H domain.
- Antigen-binding antibody fragments, including single-chain antibodies may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1 , CH2, CH3 and CL domains.
- antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1 , CH2, CH3 and CL domains.
- the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camelid, horse, or chicken.
- "human” antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries, from human B cells, or from animals transgenic for one or more human immunoglobulin, as described infra and, for example in U.S. Pat. No. 5,939,598 by Kucherlapati et al.
- the antibodies of the present disclosure may be monospecific, bispecific, trispecific or of greater multi specificity. Multispecific antibodies may be specific for different epitopes of CD30 or may be specific for both CD30 as well as for a heterologous protein. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91 /00360; WO 92/05793; Tutt, et al., 1991 , J. Immunol. 147:60 69; U.S. Pat. Nos. 4,474,893; 4,714,681 ; 4,925,648; 5,573,920; 5,601 ,819; Kostelny et al., 1992, J. Immunol. 148:1547 1553.
- Antibodies of the present disclosure may be described or specified in terms of the particular CDRs they comprise.
- antibodies of the disclosure comprise one or more CDRs of AC10.
- the disclosure encompasses an antibody or derivative thereof comprising a heavy or light chain variable domain, said variable domain comprising (a) a set of three CDRs, in which said set of CDRs are from monoclonal antibody AC10, and (b) a set of four framework regions, in which said set of framework regions differs from the set of framework regions in monoclonal antibody AC 10, and in which said antibody or derivative thereof immunospecifically binds CD30.
- the disclosure encompasses an antibody or derivative thereof comprising a heavy chain variable domain, said variable domain comprising (a) a set of three CDRs, in which said set of CDRs comprises SEQ ID NO:4, 6, or 8 and (b) a set of four framework regions, in which said set of framework regions differs from the set of framework regions in monoclonal antibody AC10, and in which said antibody or derivative thereof immunospecifically binds CD30.
- the invention encompasses an antibody or derivative thereof comprising a light chain variable domain, said variable domain comprising (a) a set of three CDRs, in which said set of CDRs comprises SEQ ID NO:12, 14 or 16, and (b) a set of four framework regions, in which said set of framework regions differs from the set of framework regions in monoclonal antibody AC10, and in which said antibody or derivative thereof immunospecifically binds CD30.
- antibodies of the present disclosure may also be described or specified in terms of their primary structures.
- Antibodies having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and most preferably at least 98% identity (as calculated using methods known in the art and described herein) to the variable regions of AC10 are also included in the present invention, and preferably include the CDRs of AC10.
- Antibodies of the present invention may also be described or specified in terms of their binding affinity to CD30.
- Preferred binding affinities include those with a dissociation constant or Kd less than 5 x10 2 M, 10 2 M, 5x10 3 M, 10 3 M, 5x10 4 M, 10 4 M, 5x1 O 5 M, 10 5 M, 5x1 O 6 M, 10 6 M, 5x10 7 M, 10 7 M, 5x1 O 8 M, 10 8 M, 5x1 O 9 M, 10 9 M, 5x1 O 10 M, 10 10 M, 5x1 O 11 M, 10 11 M, 5x1 O 12 M, 10 12 M, 5x1 O 13 M, 10 13 M, 5x1 O 14 M, 10 14 M, 5x1 O 15 M, or 10 15 M.
- the antibodies also include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from binding to CD30 or from exerting a cytostatic or cytotoxic effect on Hodgkin’s Disease cells.
- the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, PEGylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc.
- the derivative may contain one or more non-classical amino acids.
- the antibodies of the present invention may be generated by any suitable method known in the art.
- the invention further provides nucleic acids comprising a nucleotide sequence encoding a protein, including but not limited to, a protein of the invention and fragments thereof.
- Nucleic acids of the invention preferably encode one or more CDRs of antibodies that bind to CD30 and exert cytotoxic or cytostatic effects on HD cells.
- Exemplary nucleic acids of the invention comprise SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:13, or SEQ ID NO:15.
- Variable region nucleic acids of the invention comprise SEQ ID NO:1 or SEQ ID NO:9. (See Table A).
- the antibody is an IgG antibody, e.g. an lgG1 , lgG2, lgG3 or lgG4 antibody, preferably an lgG1 antibody.
- antibody drug conjugates comprising an anti-CD30 antibody, covalently linked to MMAE through a vc-PAB linker.
- the antibody drug conjugates are delivered to the subject as a pharmaceutical composition.
- CD30 antibody drug conjugates are described in US Patent No. 9,21 1 ,319, herein incorporated by reference.
- the antibody-drug conjugates of the present invention have the following formula:
- mAb is an anti-CD30 antibody
- S is a sulfur atom of the antibody
- A- is a Stretcher unit
- p is from about 3 to about 5.
- the drug loading is represented by p, the average number of drug molecules per antibody in a pharmaceutical composition.
- p the average number of drug molecules per antibody in a pharmaceutical composition.
- P ranges from about 3 to about 5, more preferably from about 3.6 to about 4.4, even more preferably from about 3.8 to about 4.2.
- P can be about 3, about 4, or about 5.
- the average number of drugs per antibody in preparation of conjugation reactions may be characterized by conventional means such as mass spectroscopy, ELISA assay, and HPLC. The quantitative distribution of antibody-drug conjugates in terms of p may also be determined.
- separation, purification, and characterization of homogeneous antibody-drug- conjugates where p is a certain value from antibody-drug-conjugates with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
- the Stretcher unit (A) is capable of linking an antibody unit to the valine-citrulline amino acid unit via a sulfhydryl group of the antibody.
- Sulfhydryl groups can be generated, for example, by reduction of the interchain disulfide bonds of an anti-CD30 antibody.
- the Stretcher unit can be linked to the antibody via the sulfur atoms generated from reduction of the interchain disulfide bonds of the antibody.
- the Stretcher units are linked to the antibody solely via the sulfur atoms generated from reduction of the interchain disulfide bonds of the antibody.
- sulfhydryl groups can be generated by reaction of an amino group of a lysine moiety of an anti-CD30 antibody with 2-iminothiolane (Traut's reagent) or other sulfhydryl generating reagents.
- the anti-CD30 antibody is a recombinant antibody and is engineered to carry one or more lysines.
- the recombinant anti-CD30 antibody is engineered to carry additional sulfhydryl groups, e.g., additional cysteines.
- the antibody drug conjugate comprises monomethyl auristatin E and a protease-cleavable linker. It is contemplated that the protease cleavable linker is comprises a thiolreactive spacer and a dipeptide. In various embodiments, the protease cleavable linker consists of a thiolreactive maleimidocaproyl spacer, a valine-citrulline dipeptide, and a p-amino-benzyloxycarbonyl spacer.
- the antibody drug conjugate is brentuximab vedotin, an antibody-drug conjugate which has the structure:
- Brentuximab vedotin is a CD30-directed antibody-drug conjugate consisting of three components: (i) the chimeric lgG1 antibody cAC10, specific for human CD30, (ii) the microtubule disrupting agent MMAE, and (iii) a protease-cleavable linker that covalently attaches MMAE to cAC10.
- the drug to antibody ratio or drug loading is represented by“p” in the structure of brentuximab vedotin and ranges in integer values from 1 to 8.
- the average drug loading brentuximab vedotin in a pharmaceutical composition is about 4.
- the chemotherapy regimen consists essentially of cyclophosphamide, doxorubicin and/or prednisone, preferably as A+CHP therapy.
- Additional chemotherapeutic agents are disclosed in the following table and may be used alone or in combination with one or more additional chemotherapeutic agents, which in turn can also be administered in combination with an anti-CD30 antibody drug conjugate.
- a peripheral T cell lymphoma refers to a hematologic cancer that expresses the CD30 antigen.
- the CD30 antigen is expressed in large numbers on tumor cells of select PTCLs, including, ALK-positive sALCL with an IPI score greater than or equal to 2, ALK- negative sALCL, PTCL-NOS, AITL, adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T-cell leukemia virus 1 ), hepatosplenic T-cell lymphoma, and enteropathy-associated T-cell lymphoma.
- the methods herein provide for treating a subject who is newly diagnosed and/or has not previously been treated for a peripheral T cell lymphoma, or a subject who has previously been treated for a peripheral T cell lymphoma, but has relapsed or the PTCL is refractory.
- the disclosure provides a method of treating a subject having newly diagnosed peripheral T cell lymphoma comprising administering an effective amount of a combination therapy comprising brentuximab vedotin in combination with a chemotherapy consisting essentially of cyclophosphamide, doxorubicin, and prednisone (CHP therapy), wherein the brentuximab vedotin is administered at 1.8 mg/kg, cyclophosphamide is
- progression free survival (PFS) of the subject after therapy is maintained for greater than 6 months or 1 year. In various embodiments, the progression free survival (PFS) of the subject after therapy is maintained for approximately 2 years. In certain embodiments, after six to eight cycles of A+CHP therapy the subject has a Deauville score of 3 or less, or 2 or less.
- the subject may receive an additional treatment to address one or more symptoms of cancer that remains at the end of treatment, or may be refractory to the therapy herein.
- treatments include, but are not limited to surgery, radiation therapy, proton beam therapy, stem cell transplant, and/or additional chemotherapeutic regimens.
- Various delivery systems can be used to administer antibody-drug conjugates.
- administration of the antibody-drug conjugate compound is by intravenous infusion. In some embodiments, administration is by a 30 minute, 1 hour or two hour intravenous infusion.
- the antibody-drug conjugate compound can be administered as a pharmaceutical composition comprising one or more pharmaceutically compatible ingredients.
- the pharmaceutical composition typically includes one or more pharmaceutically acceptable carriers, for example, water-based carriers (e.g., sterile liquids). Water is a more typical carrier when the pharmaceutical composition is administered intravenously.
- composition if desired, can also contain, for example, saline salts, buffers, salts, nonionic detergents, and/or sugars.
- suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E. W. Martin. The formulations correspond to the mode of administration.
- compositions comprising a therapeutically effective amount of the antibody-drug conjugate, a buffering agent, optionally a cryoprotectant, optionally a bulking agent, optionally a salt, and optionally a surfactant.
- Additional agents can be added to the composition.
- a single agent can serve multiple functions.
- a sugar such as trehalose, can act as both a cryoprotectant and a bulking agent.
- Any suitable pharmaceutically acceptable buffering agents, surfactants, cyroprotectants and bulking agents can be used in accordance with the present invention.
- the present invention provides antibody drug conjugate formulations including drug conjugate formulations that have undergone lyophilization, or other methods of protein preservation, as well as antibody drug formulations that have not undergone lyophilization.
- the antibody drug conjugate formulation comprises (i) about 1 - 25 mg/ml, about 3 to about 10 mg/ml of an antibody-drug conjugate, or about 5 mg/ml (e.g., an antibody-drug conjugate of formula I or a pharmaceutically acceptable salt thereof), (ii) about 5- 50 mM, preferably about 10 mM to about 25 mM of a buffer selected from a citrate, phosphate, or histidine buffer or combinations thereof, preferably sodium citrate, potassium phosphate, histidine, histidine hydrochloride, or combinations thereof, (iii) about 3% to about 10% sucrose or trehalose or combinations thereof, (iv) optionally about 0.05 to 2 mg/ml of a surfactant selected from polysorbate 20 or polysorbate 80 or combinations thereof; and (v) water, wherein the pH of the composition is from about 5.3 to about 7, preferably about 6.6.
- a buffer selected from a citrate, phosphate, or histidine buffer or combinations thereof
- an antibody drug conjugate formulation will comprise about 1 - 25 mg/ml, about 3 to about 10 mg/ml, preferably about 5 mg/ml of an antibody-drug conjugate,
- composition is from about 5.3 to about 7, preferably about 6.6.
- an antibody drug conjugate formulation will comprise about 5 mg/ml of an antibody-drug conjugate, (ii) about 10 mM to about 25 mM of a buffer selected from sodium citrate, potassium phosphate, histidine, histidine hydrochloride or combinations thereof,
- any of the formulations described above can be stored in a liquid or frozen form and can be optionally subjected to a preservation process.
- the formulations described above are lyophilized, i.e., they are subjected to lyophilization.
- the formulations described above are subjected to a preservation process, for example, lyophilization, and are subsequently reconstituted with a suitable liquid, for example, water.
- lyophilized it is meant that the composition has been freeze-dried under a vacuum.
- Lyophilization typically is accomplished by freezing a particular formulation such that the solutes are separated from the solvent(s). The solvent is then removed by sublimation (i.e., primary drying) and next by desorption (i.e., secondary drying).
- the formulations of the present disclosure can be used with the methods described herein or with other methods for treating disease.
- the antibody drug conjugate formulations may be further diluted before administration to a subject.
- the formulations of the present disclosure can be used with the methods described herein or with other methods for treating disease.
- the antibody drug conjugate formulations may be further diluted before administration to a subject.
- the compositions of the present disclosure can be used with the methods described herein or with other methods for treating disease.
- the antibody drug conjugate formulations may be further diluted before administration to a subject.
- the formulations of the present disclosure can be used with the methods described herein or with other methods for treating disease.
- the antibody drug conjugate formulations may be further diluted before administration to a subject.
- the methods for treating a mature T cell lymphoma in a subject will comprise administering to a subject in need thereof a weekly dose of a pharmaceutical composition comprising antibody-drug conjugates having formula I wherein the administered dose of antibody-drug conjugates is from about 1.8 mg/kg or 1.2 mg/kg of the subject's body weight to 0.9 mg /kg of the subject's body weight and the pharmaceutical composition is administered for at least three weeks and wherein the antibody drug conjugates, prior to administration to a subject, were present in a formulation comprising (i) about 1 -25 mg/ml, preferably about 3 to about 10 mg/ml of the antibody-drug conjugate (ii) about 5-50 mM, preferably about 10 mM to about 25 mM of a buffer selected from sodium citrate, potassium phosphate, histidine, histidine hydrochloride, or combinations thereof,
- cyclophosphamide, doxorubicin and prednisone are provided as typically used in the treatment of cancers.
- cyclophosphamide, doxorubicin, and prednisone are commercially available and approved by the United States FDA and other regulatory agencies for use in treating patients with multiple types of cancer.
- Vincristine is commercially available and approved by the United States FDA and other regulatory agencies for use in patients with multiple types of cancer.
- Administration of study treatment should be according to the institutional standard. Dosing should be based on the patient’s baseline (predose, Cycle 1 Day 1 ) height and weight or per institutional standards at the site. Vincristine is typically administered as an IV push, and will be given on Day 1 of each 21 -day cycle. Dosing should be based on the patient’s baseline (predose, Cycle 1 Day 1 ) height and weight or per institutional standards at the site.
- kits for the treatment of a mature T cell lymphoma can comprise (a) a container containing the antibody-drug conjugate and optionally, containers comprising one or more of cyclophosphamide, doxorubicin and/or prednisone.
- kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more
- Printed instructions either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
- the primary endpoint was progression-free survival per independent review facility, defined as the time from the date of randomization to the date of first documentation of progressive disease 17 , death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive T-cell lymphoma as determined by the investigator, whichever comes first.
- the latter outcome was considered an event because it represents a failure of the curative intent of frontline treatment of PTCL.
- Post treatment radiotherapy, post treatment chemotherapy for the purpose of mobilizing peripheral blood stem cells, or consolidative autologous or allogeneic SCT in the absence of progressive disease were not considered as an event.
- the key secondary endpoints were progression-free survival per independent review facility for subjects with sALCL, complete remission rate per independent review facility following the completion of study treatment, overall survival, and objective response rate (complete response + partial response).
- PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease, whichever occurred first.
- PFS is a direct reflection of tumor growth and can be assessed before determination of a survival benefit.
- PFS includes deaths from any cause it may be a correlate to OS, a secondary endpoint of this study.
- An additional advantage of PFS is that its determination is not confounded by subsequent therapy.
- post-treatment consolidative radiotherapy, post-treatment chemotherapy for the purpose of mobilizing peripheral blood stem cells, or consolidative autologous or allogeneic SCT were not considered subsequent new anticancer treatments because they are not administered to treat progressive disease.
- TRIAL DESIGN In this randomized, double-blind, active-controlled, multicenter, phase 3 trial, subjects with previously untreated, CD30-positive PTCL were randomized 1 :1 to receive 6 to 8, 21 -day cycles of either brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) or cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). A target of 6 to 8 treatment cycles was to be administered per investigator decision, based on subject-specific characteristics, including stage of disease and International
- IPI Prognostic Index
- IPI is a scoring system useful to help predict outcome of treatment. Points are given for each of the following factors a patient exhibits: age over 60, Stage III of IV cancer, more than one lymph node involved in disease, elevated serum lactate dehydrogenase; and performance scale of daily activity performance.
- PATIENTS Patients with newly diagnosed, CD30-positive peripheral T-cell lymphomas per the Revised European-American Lymphoma WHO 2008 classification by local assessment are included in the study. Eligible histologies are limited to the following: ALK- positive sALCL with an IPI score greater than or equal to 2; ALK-negative sALCL; PTCL-NOS; AITL; Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T-cell leukemia virus 1 ); Enteropathy-associated T-cell lymphoma (EATL);
- Hepatosplenic T-cell lymphoma Hepatosplenic T-cell lymphoma; Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT, as assessed by the site radiologist, and age greater than or equal to 18 years. Patients were required to have an Eastern Cooperative Oncology Group performance status ⁇ 2, and satisfactory absolute neutrophil and platelet counts, hemoglobin levels, and liver and kidney function marker levels.
- FDG Fluorodeoxyglucose
- Exclusion criteria includes history of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years.
- PML leukoencephalopathy
- Cerebral/meningeal disease related to the underlying malignancy Prior treatment with brentuximab vedotin, Baseline peripheral neuropathy 3 Grade 2 (per the NCI CTCAE, Version 4.03) or patients with the demyelinating form of Charcot-Marie-Tooth syndrome.
- ENDPOINTS The primary endpoint is modified progression-free survival (PFS), defined as time to progression, death, or evidence of non-CR after completion of frontline therapy per independent review facility (IRF). Timing of the modified event is the date of the first PET scan post-completion of frontline therapy demonstrating the absence of CR, defined as Deauville score of 33. In the absence of disease progression a switch to an alternative frontline therapy, for any reason, prior to completion of treatment with the randomized regimen was not considered an event.
- PFS progression-free survival
- IRF independent review facility
- Secondary endpoints include PFS per IRF for patients with sALCL, Complete remission (CR) rate per IRF following the completion of study treatment, Overall survival (OS) defined as time from randomization to death due to any cause, Objective response rate (ORR) per IRF following the completion of study treatment, Type, incidence, severity, seriousness, and relatedness of adverse events.
- Complete remission (CR) rate is defined as the proportion of patients with CR at the end of treatment per IRF according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007). Patients whose disease response cannot be assessed will be scored as nonresponders for calculating the CR rate.
- OS Overall survival
- ORR per IRF is defined as the proportion of patients with CR or partial remission (PR) per IRF following the completion of study treatment (at EOT) according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
- Additional Endpoints include incidence of anti-therapeutic antibodies (AT A) to brentuximab vedotin (defined as the proportion of patients that develop ATA at any time during the study), Medical Resource Utilization based on the number of medical care encounters, Quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30) and European Quality of Life 5- Dimensional (EQ-5D).
- ASSESSMENTS Response and progression are evaluated as set out above.
- Computed tomography scans are performed at screening, after Cycle 4, after the last dose of frontline therapy and, during the follow-up period, every 3 months for the first two years and 6 months thereafter.
- PET scans are conducted at screening, at the end of Cycle 4 and end of treatment.
- the FACT/GOG-NTX is a self-administered questionnaire for assessing changes in quality of life and assessment of treatment-induced neurologic symptoms (sensory, hearing, motor, and dysfunction). Patients score their well-being by selecting the frequency with which they associate with a given statement (0 being“not at all”, up to 4 being“very much”).
- the neurotoxicity subscale consists of 1 1 questions.
- the EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
- the QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and quality of life scale (Aaronson 1993).
- Subjects were randomly assigned in a 1 :1 ratio to receive 21 -day cycles of either A+CHP or CHOP for 6 or 8 cycles, with the number of cycles determined at the outset and based on investigator discretion.
- Vincristine was omitted from combination treatment with brentuximab vedotin to eliminate the potential for additional neurotoxicity. All subjects were administered the CHP components of the CHOP regimen (cyclophosphamide 750 mg/m 2 and doxorubicin 50 mg/m 2 administered IV on Day 1 of each cycle; prednisone 100 mg daily administered orally on Days 1 to 5 of each cycle).
- Randomization was stratified by histologic subtype per local pathology assessment (ALK-positive sALCL vs. all other histologies) and baseline International Prognostic Index (IPI) score 16 (0-1 vs. 2-3 vs. 4-5).
- IPI International Prognostic Index
- PFS Progression-free survival
- IRF independent review facility
- the overall response rate (ORR) at EOT by IRF assessment was 83% (95% Cl: 77.7, 87.8) for subjects on the A+CHP arm compared with 72% (95% Cl: 65.8, 77.9) for subjects on the CHOP arm.
- Tables 1 -6 show the detailed analysis on PFS per IRF and OS for various subgroups: Table 1 . Analysis on PFS per IRF and OS based on IPI Scores
- the Hazard Ratio in the tables compares clinical benefits of one treatment arm versus another in the clinical trial
- a Hazard Ratio of less than 1 means the A+CHP treatment arm provided better clinical benefits than the CHOP treatment arm
- IRF Independent Review Facility
- p-value 0.0244
- ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;1 1 1 :5496-504.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3114922A CA3114922A1 (en) | 2018-10-01 | 2019-10-01 | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
JP2021542087A JP2022502508A (en) | 2018-10-01 | 2019-10-01 | How to treat peripheral T-cell lymphoma using anti-CD30 antibody drug conjugate therapy |
KR1020217012841A KR20210069679A (en) | 2018-10-01 | 2019-10-01 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy |
AU2019355875A AU2019355875A1 (en) | 2018-10-01 | 2019-10-01 | Methods of treating peripheral T cell lymphoma using anti-CD30 antibody drug conjugate therapy |
CN201980071250.5A CN113613678A (en) | 2018-10-01 | 2019-10-01 | Methods of treating peripheral T cell lymphoma using anti-CD 30 antibody drug conjugate therapy |
EP19791017.7A EP3860658A1 (en) | 2018-10-01 | 2019-10-01 | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
SG11202103342QA SG11202103342QA (en) | 2018-10-01 | 2019-10-01 | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
MX2021003734A MX2021003734A (en) | 2018-10-01 | 2019-10-01 | Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy. |
IL281920A IL281920A (en) | 2018-10-01 | 2021-03-31 | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862739631P | 2018-10-01 | 2018-10-01 | |
US62/739,631 | 2018-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020072519A1 true WO2020072519A1 (en) | 2020-04-09 |
WO2020072519A8 WO2020072519A8 (en) | 2020-05-14 |
Family
ID=68296746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/054107 WO2020072519A1 (en) | 2018-10-01 | 2019-10-01 | Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200102399A1 (en) |
EP (1) | EP3860658A1 (en) |
JP (1) | JP2022502508A (en) |
KR (1) | KR20210069679A (en) |
CN (1) | CN113613678A (en) |
AU (1) | AU2019355875A1 (en) |
CA (1) | CA3114922A1 (en) |
IL (1) | IL281920A (en) |
MX (1) | MX2021003734A (en) |
SG (1) | SG11202103342QA (en) |
WO (1) | WO2020072519A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11814436B2 (en) | 2021-03-01 | 2023-11-14 | Nantbio, Inc. | Anti-CD30 monoclonal antibodies and chimeric antigen receptors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021231568A1 (en) * | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
US5573920A (en) | 1991-04-26 | 1996-11-12 | Surface Active Limited | Antibodies, and methods for their use |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5939598A (en) | 1990-01-12 | 1999-08-17 | Abgenix, Inc. | Method of making transgenic mice lacking endogenous heavy chains |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20060074008A1 (en) | 2002-07-31 | 2006-04-06 | Senter Peter D | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US20090010945A1 (en) | 2004-03-02 | 2009-01-08 | Seattle Genetics, Inc. | Partially Loaded Antibodies And Methods Of Their Conjugation |
US9211319B2 (en) | 2009-01-09 | 2015-12-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates |
WO2019089870A1 (en) * | 2017-11-01 | 2019-05-09 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3538221A1 (en) * | 2016-11-14 | 2019-09-18 | Millennium Pharmaceuticals, Inc. | Non-adult human dosing of anti-cd30 antibody-drug conjugates |
-
2019
- 2019-10-01 WO PCT/US2019/054107 patent/WO2020072519A1/en unknown
- 2019-10-01 SG SG11202103342QA patent/SG11202103342QA/en unknown
- 2019-10-01 CN CN201980071250.5A patent/CN113613678A/en active Pending
- 2019-10-01 CA CA3114922A patent/CA3114922A1/en active Pending
- 2019-10-01 US US16/589,914 patent/US20200102399A1/en active Pending
- 2019-10-01 EP EP19791017.7A patent/EP3860658A1/en active Pending
- 2019-10-01 MX MX2021003734A patent/MX2021003734A/en unknown
- 2019-10-01 KR KR1020217012841A patent/KR20210069679A/en unknown
- 2019-10-01 AU AU2019355875A patent/AU2019355875A1/en active Pending
- 2019-10-01 JP JP2021542087A patent/JP2022502508A/en active Pending
-
2021
- 2021-03-31 IL IL281920A patent/IL281920A/en unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5939598A (en) | 1990-01-12 | 1999-08-17 | Abgenix, Inc. | Method of making transgenic mice lacking endogenous heavy chains |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
US5573920A (en) | 1991-04-26 | 1996-11-12 | Surface Active Limited | Antibodies, and methods for their use |
WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20060074008A1 (en) | 2002-07-31 | 2006-04-06 | Senter Peter D | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20090010945A1 (en) | 2004-03-02 | 2009-01-08 | Seattle Genetics, Inc. | Partially Loaded Antibodies And Methods Of Their Conjugation |
US9211319B2 (en) | 2009-01-09 | 2015-12-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates |
WO2019089870A1 (en) * | 2017-11-01 | 2019-05-09 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
Non-Patent Citations (35)
Title |
---|
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
BOSSARD CDOBAY MPPARRENS M ET AL.: "Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels", BLOOD, vol. 124, 2014, pages 2983 - 6 |
BOWEN ET AL., J. IMMUNOL., vol. 151, 1993, pages 5896 5906 |
CHESON BDPFISTNER BJUWEID ME ET AL.: "Revised response criteria for malignant lymphoma", J CLIN ONCOL, vol. 25, 2007, pages 579 - 86 |
CLOPPER CJPEARSON ES: "The use of confidence or fiducial limits illustrated in the case of the binomial", BIOMETRIKA, vol. 26, 1934, pages 404 - 13 |
D'AMORE FRELANDER TLAURITZSEN GF ET AL.: "Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01", J CLIN ONCOL, vol. 30, 2012, pages 3093 - 9 |
FANALE MICHELLE A ET AL: "Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 120, no. 21, 31 October 2012 (2012-10-31), pages 7pp, XP009510466, ISSN: 0006-4971 * |
HIGGINS ET AL., METHODS ENZYMOL., vol. 266, 1996, pages 383 - 402 |
I. GRAVANIS ET AL: "The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use", THE ONCOLOGIST, vol. 21, no. 1, 30 November 2015 (2015-11-30), US, pages 102 - 109, XP055540408, ISSN: 1083-7159, DOI: 10.1634/theoncologist.2015-0276 * |
JANTUNEN EBOUMENDIL AFINEL H ET AL.: "Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT", BLOOD, vol. 121, 2013, pages 2529 - 32 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877 |
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 1553 |
MAHADEVAN DUNGER JMSPIER CM ET AL.: "Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350", CANCER, vol. 119, 2013, pages 371 - 9 |
MERCADAL ET AL., ANN ONCOL, vol. 19, no. 5, 2008, pages 958 - 63 |
MICHELLE A. FANALE ET AL: "Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 + Peripheral T-Cell Lymphomas: Results of a Phase I Study", JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 28, 8 December 2014 (2014-12-08), US, pages 3137 - 3143, XP055542172, ISSN: 0732-183X, DOI: 10.1200/JCO.2013.54.2456 * |
MYERSMILLER, CABIOS, 1989 |
NIELS W. C.J. VAN DE DONK ET AL: "Brentuximab vedotin", MABS, vol. 4, no. 4, 1 July 2012 (2012-07-01), US, pages 458 - 465, XP055540399, ISSN: 1942-0862, DOI: 10.4161/mabs.20230 * |
ONAINDIA AMARTINEZ NMONTES-MORENO S ET AL.: "Cd30 expression by B and T cells: A frequent finding in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified", AM J SURG PATHOL, vol. 40, 2016, pages 378 - 85 |
PEARSONLIPMAN, PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 2444 - 8 |
PERRONE GCORRADINI P: "Autologous stem cell transplantation for T-cell lymphomas", SEMINARS IN HEMATOLOGY, vol. 51, 2014, pages 59 - 66 |
REIMER PRUDIGER TGEISSINGER E ET AL.: "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study", J CLIN ONCOL, vol. 27, 2009, pages 106 - 13 |
SAVAGE KJCHHANABHAI MGASCOYNE RDCONNORS JM: "Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification", ANN ONCOL, vol. 15, 2004, pages 1467 - 75 |
SAVAGE KJHARRIS NLVOSE JM ET AL.: "ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project", BLOOD, vol. 111, 2008, pages 5496 - 504 |
SCHMITZ NTRUMPER LZIEPERT M ET AL.: "Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group", BLOOD, vol. 116, 2010, pages 3418 - 25 |
SHIPP MAHARRINGTON DPANDERSON JR ET AL.: "A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project", N ENGL J MED, vol. 329, 1993, pages 987 - 94 |
SIMON APEOCH MCASASSUS P ET AL.: "Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95", BR J HAEMATOL, vol. 151, 2010, pages 159 - 66 |
SWERDLOW SHCAMPO EHARRIS NL ET AL.: "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 2008, IARC |
TORELLISROBOTTI, COMPUT. APPL. BIOSCI., vol. 10, 1994, pages 3 - 5 |
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 69 |
VOSE JARMITAGE JWEISENBURGER D: "International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes", J CLIN ONCOL, vol. 26, 2008, pages 4124 - 30 |
WEISENBURGER DDSAVAGE KJHARRIS NL ET AL.: "Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project", BLOOD, vol. 117, 2011, pages 3402 - 8 |
WESTFALL PHKRISHEN A: "Optimally weighted, fixed sequence and gatekeeper multiple testing procedures", JOURNAL OF STATISTICAL PLANNING AND INFERENCE, vol. 99, 2001, pages 25 - 40 |
ZAJA FRUSSO DSILVESTRI F ET AL.: "Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome", HAEMATOLOGICA, vol. 82, 1997, pages 171 - 7 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11814436B2 (en) | 2021-03-01 | 2023-11-14 | Nantbio, Inc. | Anti-CD30 monoclonal antibodies and chimeric antigen receptors |
Also Published As
Publication number | Publication date |
---|---|
EP3860658A1 (en) | 2021-08-11 |
JP2022502508A (en) | 2022-01-11 |
AU2019355875A1 (en) | 2021-05-06 |
MX2021003734A (en) | 2021-07-16 |
CA3114922A1 (en) | 2020-04-09 |
IL281920A (en) | 2021-05-31 |
CN113613678A (en) | 2021-11-05 |
KR20210069679A (en) | 2021-06-11 |
US20200102399A1 (en) | 2020-04-02 |
SG11202103342QA (en) | 2021-04-29 |
WO2020072519A8 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Advani et al. | Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma | |
AU2012314390B2 (en) | Anti-ICAM-1 antibodies to treat multiple-myeloma related disorders | |
KR20210150488A (en) | Combination therapy of anti-BCMA antibody and gamma secretase inhibitor | |
JP2023154026A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
JP2020519640A (en) | Anti-CD33 immunoconjugate administration plan | |
EP3860658A1 (en) | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy | |
JP7413519B2 (en) | Methods of using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma | |
TW202120557A (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
US20150218286A1 (en) | Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin | |
US20200157228A1 (en) | Methods of treatment using anti-cd123 immunoconjugates | |
CN111526893A (en) | Methods of reducing side effects of anti-CD 30 antibody drug conjugate therapy | |
US20220347313A1 (en) | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | |
KR20240007171A (en) | Methods for treating CD20 positive proliferative disorders using mosunetuzumab and polatuzumab vedotin | |
CN116490213A (en) | Humanized anti-LIV 1 antibodies for the treatment of cancer | |
NZ710201B2 (en) | Cd37-binding molecules and immunoconjugates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19791017 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3114922 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021542087 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217012841 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019355875 Country of ref document: AU Date of ref document: 20191001 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019791017 Country of ref document: EP Effective date: 20210503 |